替加环素联合头孢哌酮舒巴坦对多重耐药鲍曼不动杆菌肺部感染患者的临床疗效及机制探讨

发布时间：2018-06-22 14:34

本文选题：替加环素 + 多重耐药鲍曼不动杆菌　；参考：《中国医院药学杂志》2017年05期

【摘要】：目的:探讨替加环素联合头孢哌酮舒巴坦对多重耐药鲍曼不动杆菌肺部感染患者血清降钙素原(procalcitonin,PCT)水平的影响。方法:选取来海南省人民医院治疗的多重耐药鲍曼不动杆菌肺部感染患者70例,按随机数字表法分组,对照组35例予以头孢哌酮舒巴坦治疗,研究组35例在对照组基础上予以替加环素治疗,采血测定两组患者临床相应指标及免疫水平,对比临床疗效及细菌清除率状况。结果:对照组治疗有效率80%低于研究组治疗有效率91.44%,无统计学差异(P0.05);对照组细菌清除率71.43%低于研究组细菌清除率91.44%,具有统计学意义(P0.05);与对照组比较,研究组治疗后血清乳酸(lactate,LAC)、PCT水平均显著降低,治疗后IgA降低,IgM、IgG升高,具有统计学意义(P0.05)。结论:替加环素联合头孢哌酮舒巴坦对多重耐药鲍曼不动杆菌肺部感染效果显著,降低PCT水平,提高免疫功能。
[Abstract]:Aim: to investigate the effect of tegicycline combined with cefoperazone sulbactam on serum procalcitonin PCT levels in patients with multidrug resistant Acinetobacter baumannii pulmonary infection. Methods: seventy patients with multiple drug-resistant Acinetobacter baumannii pulmonary infection treated in Hainan Provincial people's Hospital were randomly divided into two groups: the control group (n = 35) was treated with cefoperazone sulbactam. 35 patients in the study group were treated with tegicycline on the basis of the control group. The clinical indexes and immune level of the two groups were measured and the clinical efficacy and bacterial clearance rate were compared between the two groups. Results: the effective rate of treatment in the control group was 80% lower than that in the study group (91.44%), there was no statistical difference (P0.05), the bacterial clearance rate in the control group (71.43%) was lower than that in the study group (91.44%) (P0.05). After treatment, the levels of lactate LAC and serum PCT in the study group were significantly decreased, and the level of IgA decreased after treatment, which had statistical significance (P0.05). Conclusion: tigicycline combined with cefoperazone sulbactam has a significant effect on pulmonary infection of Acinetobacter baumannii with multidrug resistance, which can decrease the level of PCT and improve immune function.
【作者单位】：海南省儋州市第一人民医院检验科;海南省人民医院检验科微生物室;
【分类号】：R563.1

【参考文献】